Johnson & Johnson has moved a step closer to filing a potential first-in-class therapy for psoriasis after the drug hit the mark in a phase 3 trial. Once-daily oral IL-23 inhibitor icotrokinra ...
Oh, sure, I can “code.” That is, I can flail my way through a block of (relatively simple) pseudocode and follow the flow. I ...
This transcript was created using speech recognition software. While it has been reviewed by human transcribers, it may contain errors. Please review the episode audio before quoting from this ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results